Could the Rush to a Vaccine Hurt Coronavirus Stocks?
Nearly 6.2 million people worldwide are confirmed to have contracted COVID-19, more than 376,000 people have died, and the pandemic is far from over. So with containment of the coronavirus pandemic proving to be a challenge, many people are pinning their hopes on a vaccine.
There are more than 120 SARS-CoV-2 vaccine programs ongoing at companies or universities, and 10 have already reached the human trial stage. As these programs progress, developers' share prices have climbed, and clinical-stage biotech companies have gotten particularly big boosts. For example, Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX), and Inovio Pharmaceuticals (NASDAQ: INO) have soared by 203%, 1,100%, and 330%, respectively, since the start of the year.
Image source: Getty Images.
Source Fool.com
